Our FDA and digital health teams recently published a LawFlash on how a Biden administration will affect the US Food and Drug Administration’s (FDA’s) oversight and regulation of medical devices and digital health.
Legal Insights and Perspectives for the Healthcare Industry
Proposed reforms to patent subject matter eligibility in the United States are once again making headlines. With advancements in medical device technologies and the increasing integration of software, patent eligibility considerations implicate a growing realm of medical devices.
On a fourth go-around, the Trump administration has issued another set of proposed tariffs on an additional $300 billion of goods related to China, this time adding a range of commercial goods across industries.